Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis.

To access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.Hydroxyethyl starch (HES) [corrected] is widely used for fluid resuscitation in intensive care units (ICUs), but its safety and efficacy have not been established in patients with severe sepsis. In this multicenter, parallel-group, blinded trial, we randomly assigned patients with severe sepsis to fluid resuscitation in the ICU with either 6% HES 130/0.42 (Tetraspan) or Ringer's acetate at a dose of up to 33 ml per kilogram of ideal body weight per day. The primary outcome measure was either death or end-stage kidney failure (dependence on dialysis) at 90 days after randomization. Of the 804 patients who underwent randomization, 798 were included in the modified intention-to-treat population. The two intervention groups had similar baseline characteristics. At 90 days after randomization, 201 of 398 patients (51%) assigned to HES 130/0.42 had died, as compared with 172 of 400 patients (43%) assigned to Ringer's acetate (relative risk, 1.17; 95% confidence interval [CI], 1.01 to 1.36; P=0.03); 1 patient in each group had end-stage kidney failure. In the 90-day period, 87 patients (22%) assigned to HES 130/0.42 were treated with renal-replacement therapy versus 65 patients (16%) assigned to Ringer's acetate (relative risk, 1.35; 95% CI, 1.01 to 1.80; P=0.04), and 38 patients (10%) and 25 patients (6%), respectively, had severe bleeding (relative risk, 1.52; 95% CI, 0.94 to 2.48; P=0.09). The results were supported by multivariate analyses, with adjustment for known risk factors for death or acute kidney injury at baseline. Patients with severe sepsis assigned to fluid resuscitation with HES 130/0.42 had an increased risk of death at day 90 and were more likely to require renal-replacement therapy, as compared with those receiving Ringer's acetate. (Funded by the Danish Research Council and others; 6S ClinicalTrials.gov number, NCT00962156.)Danish Research Council 271-08-0691 09-066938 Rigshospitalet Research Council Scandinavian Society of Anesthesiology and Intensive Care Medicine ACTA Foundation Fresenius Kab

Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S-Scandinavian Starch for Severe Sepsis/Septic Shock trial): Study protocol, design and rationale for a double-blinded, randomised clinical trial

Peer reviewe

Les ventilateurs d’anesthésie actuels exposent à une importante «dépense d’oxygène»

To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldPURPOSE: Anesthesia ventilators use oxygen or oxygen/air mixtures to drive the bellows during controlled ventilation. As a practitioner may find himself in a situation that the only available oxygen source is a compressed oxygen cylinder, it is important to know the oxygen consumption of anesthesia ventilators during controlled ventilation. METHODS: We tested the Datex-Ohmeda 7900 ventilator mounted on an Excel 210 anesthesia machine under a variety of conditions. For comparison, we also tested the Ohmeda 7800 and the Dräger AV-2 ventilator under control conditions. All experiments were performed using a test lung. RESULTS: The oxygen consumption of the AV-2 and the Datex-Ohmeda ventilators averaged 302 +/- 17 L x hr(-1) and 564 +/- 68 to 599 +/- 56 L x hr(-1), respectively (P < 0.01 AV-2 vs 7800 and 7900). When using an E-type cylinder, this would result in a mean time to alarm of 93 min and 54 to 57 min, respectively. Decreased lung compliance increased the oxygen consumption to 848 +/- 16 L x hr(-1). CONCLUSIONS: Machine-driven mechanical ventilation incurs a significant "oxygen cost." We show that the amount of oxygen consumed by mechanical ventilation with contemporary anesthesia ventilators is influenced by patient-dependent factors and may greatly exceed the amount of oxygen delivered to the patient

Les ventilateurs d’anesthésie actuels exposent à une importante «dépense d’oxygène»

To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldPURPOSE: Anesthesia ventilators use oxygen or oxygen/air mixtures to drive the bellows during controlled ventilation. As a practitioner may find himself in a situation that the only available oxygen source is a compressed oxygen cylinder, it is important to know the oxygen consumption of anesthesia ventilators during controlled ventilation. METHODS: We tested the Datex-Ohmeda 7900 ventilator mounted on an Excel 210 anesthesia machine under a variety of conditions. For comparison, we also tested the Ohmeda 7800 and the Dräger AV-2 ventilator under control conditions. All experiments were performed using a test lung. RESULTS: The oxygen consumption of the AV-2 and the Datex-Ohmeda ventilators averaged 302 +/- 17 L x hr(-1) and 564 +/- 68 to 599 +/- 56 L x hr(-1), respectively (P < 0.01 AV-2 vs 7800 and 7900). When using an E-type cylinder, this would result in a mean time to alarm of 93 min and 54 to 57 min, respectively. Decreased lung compliance increased the oxygen consumption to 848 +/- 16 L x hr(-1). CONCLUSIONS: Machine-driven mechanical ventilation incurs a significant "oxygen cost." We show that the amount of oxygen consumed by mechanical ventilation with contemporary anesthesia ventilators is influenced by patient-dependent factors and may greatly exceed the amount of oxygen delivered to the patient

Cardiac myxoma in Iceland: a case series with an estimation of population incidence.

To access publisher full text version of this article. Please click on the hyperlink in Additional Links field.Cardiac myxoma (CM) is the most common primary benign tumor of the heart, but the true age-standardized incidence rate (ASR) has remained unknown. We therefore used nationwide registries in Iceland to study CM and establish its incidence rate. This was a retrospective study involving all patients diagnosed with CM in Iceland between 1986 and 2010. Cases were identified through three different registries, and hospital charts and histology results reviewed. An ASR was estimated based on a world standard population (w). Nine cases of CM (six women) were identified with a mean age of 62.8 years (range: 37-85), giving an ASR of 0.11 (95% CI: 0.05-0.22) per 100,000. The mean tumor size was 4.4 cm (range: 1.5-8.0) with all the tumors located in the left atrium. Dyspnea (n = 6) and ischemic stroke (n = 2) were the most common symptoms. All patients underwent complete resection of the tumor and there were no postoperative deaths or CM-related deaths at follow-up (mean 85 months). The ASR of CM in Iceland was 0.11 per 100,000. To our knowledge, this is the first study to determine the incidence of CM in an entire population. In Iceland, the presenting symptoms and mode of detection of CM are similar to those in other series

Long-term outcomes in patients with severe sepsis randomised to resuscitation with hydroxyethyl starch 130/0.42 or Ringer's acetate.

To access publisher's full text version of this article click on the hyperlink at the bottom of the pageWe assessed long-term mortality and hospitalisation in patients with severe sepsis resuscitated with hydroxyethyl starch (HES) or Ringer's acetate.This was an investigator-initiated, parallel-grouped, blinded randomised trial using computer-generated allocation sequence and centralised allocation data that included 804 patients with severe sepsis needing fluid resuscitation in 26 general intensive care units (ICUs) in Scandinavia. Patients were allocated to fluid resuscitation using either 6% HES 130/0.42 or Ringer's acetate during ICU admission. We assessed mortality rates at 6 months, 1 year and at the time of longest follow-up and days alive and out of hospital at 1 year.The vital status of all patients was obtained at a median of 22 (range 13-36) months after randomisation. Mortality rates in the HES versus Ringer's groups at 6 months were 53.3 (212/398 patients) versus 47.5% (190/400) [relative risk 1.12; 95% confidence interval (CI) 0.98-1.29; P = 0.10], respectively; at 1 year, 56.0 (223/398) versus 51.5% (206/400) (1.09; 95% CI 0.96-1.24; P = 0.20), respectively; at the time of longest follow-up, 59.8 (238/398) versus 56.3% (225/400) (1.06; 95% CI 0.94-1.20; P = 0.31), respectively. Percentage of days alive and out of hospital at 1 year in the HES versus Ringer's groups was 24 (0-87 days) versus 63% (0-90) (P = 0.07).The long-term mortality rates did not differ in patients with severe sepsis assigned to HES 130/0.42 versus Ringer's acetate, but we could not reject a 24% relative increased or a 4% relative decreased mortality at 1 year with HES at the 95% confidence level.Department of Intensive Care, Copenhagen University Hospital, Rigshospitalet, 2100 Copenhagen, Denmark b Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital, 2100 Copenhagen, Denmark c Department of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway d Department of Clinical Medicine 1, University of Bergen, Bergen, Norway e Critical Care Medicine Research Group, Department of Intensive Care Medicine, Tampere University Hospital, Tampere, Finland f Department of Surgical Sciences/Anesthesiology and Intensive Care, Uppsala University, Uppsala, Sweden g Department of Anaesthesia and Intensive Care, Landspitali, Reykjavik, Iceland h Department of Intensive Care, Liverpool Hospital, Sydney, NSW, Australi

Transfusion requirements in septic shock (TRISS) trial - comparing the effects and safety of liberal versus restrictive red blood cell transfusion in septic shock patients in the ICU:protocol for a randomised controlled trial

BACKGROUND: Transfusion of red blood cells (RBC) is recommended in septic shock and the majority of these patients receive RBC transfusion in the intensive care unit (ICU). However, benefit and harm of RBCs have not been established in this group of high-risk patients. METHODS/DESIGN: The Transfusion Requirements in Septic Shock (TRISS) trial is a multicenter trial with assessor-blinded outcome assessment, randomising 1,000 patients with septic shock in 30 Scandinavian ICUs to receive transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM) at haemoglobin level (Hb) of 7 g/dl or 9 g/dl, stratified by the presence of haematological malignancy and centre. The primary outcome measure is 90-day mortality. Secondary outcome measures are organ failure, ischaemic events, severe adverse reactions (SARs: anaphylactic reaction, acute haemolytic reaction and transfusion-related circulatory overload, and acute lung injury) and mortality at 28 days, 6 months and 1 year. The sample size will enable us to detect a 9% absolute difference in 90-day mortality assuming a 45% event rate with a type 1 error rate of 5% and power of 80%. An interim analysis will be performed after 500 patients, and the Data Monitoring and Safety Committee will recommend the trial be stopped if a group difference in 90-day mortality with P ≤0.001 is present at this point. DISCUSSION: The TRISS trial may bridge the gap between clinical practice and the lack of efficacy and safety data on RBC transfusion in septic shock patients. The effect of restrictive versus liberal RBC transfusion strategy on mortality, organ failure, ischaemic events and SARs will be evaluated. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01485315. Registration date 30 November 2011. First patient was randomised 3 December 2011